Volume 16, Number 12—December 2010
CME ACTIVITY - Dispatch
Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, South Korea
Table 1
Patient | Age, y/ sex | Antiviral treatment and date | Date of specimen collection | Type of clinical specimen | Underlying condition |
---|---|---|---|---|---|
A | 5/M | Oseltamivir, 30 mg 2×/d (Oct 29–Nov 4); 60 mg 2×/d (Nov 5–9) | Nov 6 | Nasopharyngeal swab | Mitochondrial cytopathic changes (bedridden) |
B | 46/M | Oseltamivir, 150 mg 2×/d (Nov 6–15); zanamivir, 10 mg 2×/d (Nov 16–26) | Nov 18 | Nasopharyngeal swab | Leukemia |
C | 1/F | Oseltamivir, 30 mg 2×/d (Nov 16–21); 60 mg 2×/d (Nov 22–Dec 8) | Nov 21 and 22 | Nasopharyngeal swab | Brain damage (fatal) |
D | 2/M | Oseltamivir, 90 mg 2×/d (Nov 26–30); 180 mg and amantadine, 65 mg 2×/d (Dec 2–7) | Nov 22, Dec 2 | Nasal suction | None |
E | 3/F | Oseltamivir, 30 mg 2×/d (Dec 1–5 and 7–11) | Dec 1, 7, and 9 | Oropharyngeal swab (Dec 1, 7); nasopharyngeal swab (Dec 9) | Asthma |
F | 3/F | Oseltamivir, 45 mg 2×/d (Dec 10–15); 75 mg 2×/d (Dec 16–20) | Dec 18 | Oropharyngeal swab | Delayed development |
G | 1/F | Oseltamivir, 30 mg 2×/d (Dec 1–5); peramivir, 75 mg 1×/day (Dec 12–18) | Dec 1, 5, and 15 | Nasal/oropharyngeal swab | Myelodysplasia (fatal) |
H | 63/M | Oseltamivir, 150 mg 2×/d (Dec 7–15); zanamivir, 10 mg 2×/d (Dec 16–20) | Dec 16 | Oropharyngeal swab | Diabetes |
I | 58/M | Oseltamivir, 150 mg 2×/d (Dec 16–18); peramivir, 600 mg 1×/d, amantadine, 100 mg 2×/d a day, ribavirin, 300 mg 1×/d (Dec 19–25); zanamivir, 10 mg 2×/d (Dec 26–2010 Jan 1) | Dec 26 | Nasopharyngeal swab | Cancer |
J | 60/M | Oseltamivir, 75 mg 2×/d (Nov 30–Dec 2) | Dec 1 | Viral RNA | Diabetes, cardiac disorders (fatal) |
Page created: August 28, 2011
Page updated: August 28, 2011
Page reviewed: August 28, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.